Seattle Genetics, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 78   

Articles published

SGEN 34.53 +0.33 (0.96%)
price chart
Seattle Genetics And Agios Pharmaceuticals: Opportunity Or Danger?
The first company is $4 billion Seattle Genetics (NASDAQ:SGEN), best known for its breakthrough approach to cancer through antibody-drug conjugate technology.
Related articles »  
Today's Water-Logged And Getting Wetter Stock: Seattle Genetics (SGEN)
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Trade-Ideas LLC identified Seattle Genetics ( SGEN) as a "water-logged ...
Seattle Genetics: Good Tech, But On The Wrong Path (SGEN)
When I first started following Seattle Genetics (NASDAQ:SGEN) in Sep, 2013, it appeared to be a very promising mid-cap company with a broad pipeline and advanced ADC (antibody-drug conjugate) technology. However, as time went by, my attitude towards ...
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day  Nasdaq
Related articles »  
Kinder Morgan, Seattle Genetics And Others Insiders Have Been Buying
So far in March, one director has obtained more than 773,000 shares of Seattle Genetics, Inc. (NASDAQ: SGEN) for more than $25.5 million.
Earnings Watch: Seattle Genetics, Inc. (NASDAQ:SGEN)
When Seattle Genetics, Inc. (NASDAQ:SGEN) reports their next earnings announcement on or around 2015-04-30, investors will be paying particularly close attention to the reported earnings per share number versus the Wall Street analyst estimates.
Seattle Genetics Adcetris Under Review for New Indication  Zacks.com
Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog  Nasdaq
FDA accepts Seattle Genetics' filing for Adcetris expanded indication (SGEN)
... for the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemo regimen.
Seattle Genetics Says FDA Accepts SBLA, Grants Priority Review For ADCETRIS  RTT News
FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS ...  MarketWatch
Analysts Views: Seattle Genetics, Inc. (NASDAQ:SGEN)
Wall Street Equity Research analysts evaluating future earnings growth for Seattle Genetics, Inc. (NASDAQ:SGEN), are predicting that the company will report $-0.19 for the quarter ending on 2015-03-31.
Seattle Genetics (SGEN) Set to Announce Quarterly Earnings on Thursday  WKRB News
Seattle Genetics to Present at Upcoming Investor Conferences  MarketWatch
Seattle Genetics Inc. (SGEN) is Trading Lower on Unusual Volume for April 30
Seattle Genetics Inc. (SGEN) experienced unusually high volume on Apr. 30, as the stock lost 2.08% to a closing price of $34.34.
Seattle Genetics Becomes Oversold (SGEN)
In trading on Friday, shares of Seattle Genetics Inc (NASD: SGEN) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $32.68 per share.
Update: Short Interest of Seattle Genetics, Inc. Drops by -1.9%
The short interest in Seattle Genetics, Inc. (NASDAQ:SGEN) has declined from 18,790,279 on March 13,2015 to 18,431,370 on March 31,2015 .
Seattle Genetics to Host Conference Call and Webcast Discussion of First ...  Business Wire (press release)